Abstract
Familial glucocorticoid deficiency (FGD), otherwise known as hereditary unresponsiveness to ACTH, is a rare autosomal recessive disease characterized by glucocorticoid deficiency in the absence of mineralocorticoid deficiency. Mutations of the ACTH receptor, also known as the melanocortin-2 receptor (MC2R), account for approximately 25% of FGD cases. More recently a second gene, MRAP (melanocortin-2 receptor accessory protein), was identified and found to account for a further 15–20%. MRAP encodes a small single transmembrane domain protein, which is essential in the trafficking of the MC2R to the cell surface. In this review, we will firstly summarize the clinical presentation and genetic aetiology of this condition. Secondly, we will discuss how the discovery of MRAP has enhanced our understanding of the mechanisms of ACTH/MC2R action. Finally, we will explore future developments in this field.
References
1.
Huebner A, Kaindl AM, Knobeloch KP, Petzold H, Mann P, Koehler K: The triple A syndrome is due to mutations in ALADIN, a novel member of the nuclear pore complex. Endocr Res 2004;30:891–899.
2.
Shepard TH, Landing BH, Mason DG: Familial Addison’s disease; case reports of two sisters with corticoid deficiency unassociated with hypoaldosteronism. AMA J Dis Child 1959;97:154–162.
3.
Thistlethwaite D, Darling JA, Fraser R, Mason PA, Rees LH, Harkness RA: Familial glucocorticoid deficiency. Studies of diagnosis and pathogenesis. Arch Dis Child 1975;50:291–297.
4.
Thistlethwaite D, Darling JA, Fraser R, Rees LH, Harkness RA: Proceedings: familial glucocorticoid deficiency. J Endocrinol 1974;63:48P–49P.
5.
Spark RF, Etzkorn JR: Absent aldosterone response to ACTH in familial glucocorticoid deficiency. N Engl J Med 1977;297:917–920.
6.
Clark AJ, McLoughlin L, Grossman A: Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 1993;341:461–462.
7.
Mountjoy KG, Robbins LS, Mortrud MT, Cone RD: The cloning of a family of genes that encode the melanocortin receptors. Science 1992;257:1248–1251.
8.
Clark AJ, Weber A: Adrenocorticotropin insensitivity syndromes. Endocr Rev 1998;19:828–843.
9.
Lin L, Hindmarsh PC, Metherell LA, Alzyoud M, Al Ali M, Brain CE, et al: Severe loss-of-function mutations in the adrenocorticotropin receptor (ACTHR, MC2R) can be found in patients diagnosed with salt-losing adrenal hypoplasia. Clin Endocrinol 2007;66:205–210.
10.
Lacy DE, Nathavitharana KA, Tarlow MJ: Neonatal hepatitis and congenital insensitivity to adrenocorticotropin (ACTH). J Pediatr Gastroenterol Nutr 1993;17:438–440.
11.
Modan-Moses D, Ben Zeev B, Hoffmann C, Falik-Zaccai TC, Bental YA, Pinhas-Hamiel O, et al: Unusual presentation of familial glucocorticoid deficiency (FGD) with a novel MRAP mutation. J Clin Endocrinol Metab 2006;91:3713–3717.
12.
Elias LL, Huebner A, Metherell LA, Canas A, Warne GL, Bitti ML, et al: Tall stature in familial glucocorticoid deficiency. Clin Endocrinol (Oxf) 2000;53:423–430.
13.
Imamine H, Mizuno H, Sugiyama Y, Ohro Y, Sugiura T, Togari H: Possible relationship between elevated plasma ACTH and tall stature in familial glucocorticoid deficiency. Tohoku J Exp Med 2005;205:123–131.
14.
Zhong Q, Sridhar S, Ruan L, Ding KH, Xie D, Insogna K, et al: Multiple melanocortin receptors are expressed in bone cells. Bone 2005;36:820–831.
15.
Mountjoy KG, Jenny Wu CS, Dumont LM, Wild JM: Melanocortin-4 receptor messenger ribonucleic acid expression in rat cardiorespiratory, musculoskeletal, and integumentary systems. Endocrinology 2003;144:5488–5496.
16.
Selva KA, Lafranchi SH, Boston B: A novel presentation of familial glucocorticoid deficiency (FGD) and current literature review. J Pediatr Endocrinol Metab 2004;17:85–92.
17.
Weber A, Clark AJ, Perry LA, Honour JW, Savage MO: Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Clin Endocrinol (Oxf) 1997;46:431–437.
18.
Ishii T, Ogata T, Sasaki G, Sato S, Kinoshita EI, Matsuo N: Novel mutations of the ACTH receptor gene in a female adult patient with adrenal unresponsiveness to ACTH. Clin Endocrinol (Oxf) 2000;53:389–392.
19.
Suda T, Yajima F, Tomori N, Sumitomo T, Nakagami Y, Ushiyama T, et al: Inhibitory effect of adrenocorticotropin on corticotropin-releasing factor release from rat hypothalamus in vitro. Endocrinology 1986;118:459–461.
20.
Suda T, Tomori N, Yajima F, Ushiyama T, Sumitomo T, Nakagami Y, et al: A short negative feedback mechanism regulating corticotropin-releasing hormone release. J Clin Endocrinol Metab 1987;64:909–913.
21.
Boscaro M, Sonino N, Paoletta A, Rampazzo A, Mantero F: Evidence for ultra-short loop autoregulation of adrenocorticotropin secretion in man. J Clin Endocrinol Metab 1988;66:255–257.
22.
Morris DG, Kola B, Borboli N, Kaltsas GA, Gueorguiev M, McNicol AM, et al: Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. J Clin Endocrinol Metab 2003;88:6080–6087.
23.
Brook CGD, Clayton PE, Brown SB: Clinical Pediatric Endocrinology, ed 5. Oxford, Blackwell, 2005.
24.
Davidai G, Kahana L, Hochberg Z: Glomerulosa failure in congenital adrenocortical unresponsiveness to ACTH. Clin Endocrinol (Oxf) 1984;20:515–520.
25.
Xia Y, Wikberg JE: Localization of ACTH receptor mRNA by in situ hybridization in mouse adrenal gland. Cell Tissue Res 1996;286:63–68.
26.
Reincke M, Beuschlein F, Menig G, Hofmockel G, Arlt W, Lehmann R, et al: Localization and expression of adrenocorticotropic hormone receptor mRNA in normal and neoplastic human adrenal cortex. J Endocrinol 1998;156:415–423.
27.
Arvat E, Di Vito L, Lanfranco F, Maccario M, Baffoni C, Rossetto R, et al: Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J Clin Endocrinol Metab 2000;85:3141–3146.
28.
Weise K, Zaritsky A: Endocrine manifestations of critical illness in the child. Pediatr Clin North Am 1987;34:119–130.
29.
Perry R, Kecha O, Paquette J, Huot C, Van Vliet G, Deal C: Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab 2005;90:3243–3250.
30.
Migeon CJ, Kenny EM, Kowarski A, Snipes CA, Spaulding JS, Finkelstein JW, et al: The syndrome of congenital adrenocortical unresponsiveness to ACTH. Report of six cases. Pediatr Res 1968;2:501–513.
31.
Kelch RP, Kaplan SL, Biglieri EG, Daniels GH, Epstein CJ, Grumbach MM: Hereditary adrenocortical unresponsiveness to adrenocorticotropic hormone. J Pediatr 1972;81:726–736.
32.
Crown A, Lightman S: Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf) 2005;63:483–492.
33.
Mountjoy KG, Robbins LS, Mortrud MT, Cone RD: The cloning of a family of genes that encode the melanocortin receptors. Science 1992;257:1248–1251.
34.
Tsigos C, Arai K, Hung W, Chrousos GP: Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest 1993;92:2458–2461.
35.
Tsigos C, Arai K, Latronico AC, DiGeorge AM, Rapaport R, Chrousos GP: A novel mutation of the adrenocorticotropin receptor (ACTH-R) gene in a family with the syndrome of isolated glucocorticoid deficiency, but no ACTH-R abnormalities in two families with the triple A syndrome. J Clin Endocrinol Metab 1995;80:2186–2189.
36.
Weber A, Toppari J, Harvey RD, Klann RC, Shaw NJ, Ricker AT, et al: Adrenocorticotropin receptor gene mutations in familial glucocorticoid deficiency: relationships with clinical features in four families. J Clin Endocrinol Metab 1995;80:65–71.
37.
Naville D, Penhoat A, Barjhoux L, Jaillard C, Fontanay S, Saez J, et al: Characterization of the human ACTH receptor gene and in vitro expression. Endocr Res 1996;22:337–348.
38.
Wu SM, Stratakis CA, Chan CH, Hallermeier KM, Bourdony CJ, Rennert OM, et al: Genetic heterogeneity of adrenocorticotropin (ACTH) resistance syndromes: identification of a novel mutation of the ACTH receptor gene in hereditary glucocorticoid deficiency. Mol Genet Metab 1998;64:256–265.
39.
Slavotinek AM, Hurst JA, Dunger D, Wilkie AO: ACTH receptor mutation in a girl with familial glucocorticoid deficiency. Clin Genet 1998;53:57–62.
40.
Naville D, Penhoat A, Durand P, Begeot M: Three steroidogenic factor-1 binding elements are required for constitutive and cAMP-regulated expression of the human adrenocorticotropin receptor gene. Biochem Biophys Res Commun 1999;255:28–33.
41.
Elias LL, Huebner A, Pullinger GD, Mirtella A, Clark AJ: Functional characterization of naturally occurring mutations of the human adrenocorticotropin receptor: poor correlation of phenotype and genotype. J Clin Endocrinol Metab 1999;84:2766–2770.
42.
Naville D, Barjhoux L, Jaillard C, Faury D, Despert F, Esteva B, et al: Demonstration by transfection studies that mutations in the adrenocorticotropin receptor gene are one cause of the hereditary syndrome of glucocorticoid deficiency. J Clin Endocrinol Metab 1996;81:1442–1448.
43.
Naville D, Barjhoux L, Jaillard C, Saez JM, Durand P, Begeot M: Stable expression of normal and mutant human ACTH receptor: study of ACTH binding and coupling to adenylate cyclase. Mol Cell Endocrinol 1997;129:83–90.
44.
Fluck CE, Martens JW, Conte FA, Miller WL: Clinical, genetic, and functional characterization of adrenocorticotropin receptor mutations using a novel receptor assay. J Clin Endocrinol Metab 2002;87:4318–4323.
45.
Yanovski JA, Yanovski SZ, Gold PW, Chrousos GP: Differences in the hypothalamic-pituitary-adrenal axis of black and white women. J Clin Endocrinol Metab 1993;77:536–541.
46.
Yanovski JA, Yanovski SZ, Harrington L, Gold PW, Chrousos GP: Differences in the hypothalamic-pituitary-adrenal axis of black and white men. Horm Res 1995;44:208–212.
47.
Naville D, Weber A, Genin E, Durand P, Clark AJ, Begeot M: Exclusion of the adrenocorticotropin (ACTH) receptor (MC2R) locus in some families with ACTH resistance but no mutations of the MC2R coding sequence (familial glucocorticoid deficiency type 2). J Clin Endocrinol Metab 1998;83:3592–3596.
48.
Weber A, Clark AJ: Mutations of the ACTH receptor gene are only one cause of familial glucocorticoid deficiency. Hum Mol Genet 1994;3:585–588.
49.
Genin E, Huebner A, Jaillard C, Faure A, Halaby G, Saka N, et al: Linkage of one gene for familial glucocorticoid deficiency type 2 (FGD2) to chromosome 8q and further evidence of heterogeneity. Hum Genet 2002;111:428–434.
50.
Noon LA, Franklin JM, King PJ, Goulding NJ, Hunyady L, Clark AJ: Failed export of the adrenocorticotrophin receptor from the endoplasmic reticulum in non-adrenal cells: evidence in support of a requirement for a specific adrenal accessory factor. J Endocrinol 2002;174:17–25.
51.
Rached M, El Mourabit H, Buronfosse A, Blondet A, Naville D, Begeot M, et al: Expression of the human melanocortin-2 receptor in different eukaryotic cells. Peptides 2005;26:1842–1847.
52.
Metherell LA, Chapple JP, Cooray S, David A, Becker C, Ruschendorf F, et al: Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 2005;37:166–170.
53.
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333–339.
54.
Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H: RTP family members induce functional expression of mammalian odorant receptors. Cell 2004;119:679–691.
55.
Behrens M, Bartelt J, Reichling C, Winnig M, Kuhn C, Meyerhof W: Members of RTP and REEP gene families influence functional bitter taste receptor expression. J Biol Chem 2006;281:20650–20659.
56.
Roy S, Rached M, Gallo-Payet N: Differential regulation of the human adrenocorticotropin receptor [melanocortin-2 receptor (MC2R)] by human MC2R accessory protein isoforms alpha and beta in isogenic human embryonic kidney 293 cells. Mol Endocrinol 2007;21:1656–1669.
57.
Huber C, Dias-Santagata D, Glaser A, O’Sullivan J, Brauner R, Wu K, et al: Identification of mutations in CUL7 in 3-M syndrome. Nat Genet 2005;37:1119–1124.
58.
Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004;36:228–230.
59.
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A: Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155–157.
60.
Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O’Rahilly S: A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998;20:111–112.
61.
Lubrano-Berthelier C, Dubern B, Lacorte JM, Picard F, Shapiro A, Zhang S, et al: Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab 2006;91:1811–1818.
62.
Clark AJ, Metherell LA, Cheetham ME, Huebner A: Inherited ACTH insensitivity illuminates the mechanisms of ACTH action. Trends Endocrinol Metab 2005;16:451–457.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
